Drug Profile
Research programme: immunological disorder therapeutics - Jeffrey Modell Foundation/Pfizer Centers for Therapeutic Innovation
Latest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator Jeffrey Modell Foundation; Pfizer Centers for Therapeutic Innovation
- Developer Pfizer Centers for Therapeutic Innovation
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for research development in Immunological-disorders in USA
- 08 Jul 2015 Pfizer’s Centers for Therapeutic Innovation and the Jeffrey Modell Foundation agree to co-develop therapeutics for immunological disorders
- 08 Jul 2015 Early research in Immunological disorders in USA (unspecified route)